2C-C-NBOMe (NBOMe-2C-C, 25C-NBOMe, Cimbi-82, Pandora, Dime) is a derivative of the phenethylamine hallucinogen 2C-C, which acts as a potent partial agonist for the 5HT_2A receptor, and has been studied in its ¹¹C radiolabelled form as a potential ligand for mapping the distribution of 5-HT_2A receptors in the brain, using positron emission tomography (PET). Anecdotal reports from human users suggest 2C-C-NBOMe to be an active hallucinogen at a dose of as little as 200-500mcg insufflated, making it only slightly less potent than LSD.^{[citation needed]} It was discovered to be on sale as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and therefore a Class C controlled drug analogue.